Our study had some limitations, such as the low number of extra-GI primary neoplasms in EPCAM deletion carriers, especially endometrial carcinoma, not allowing to know the usefulness of EPCAM IHC in this type of carcinomas. The gene discussed is EPCAM; the disease is carcinoma.